BOUCHERVILLE, QC, July 2, 2025 /CNW/ - LSL PHARMA GROUP INC. (TSXV: LSL) ("LSL Pharma" or the "Corporation"), a Canadian integrated pharmaceutical company, is pleased to announce that TSX Trust Company (the "Trustee"), in accordance with the trust indenture dated November 1, 2023 between the Corporation and the Trustee (the "Indenture"), will be providing notice of early redemption of all of the Corporation's outstanding $3,288,000 aggregate principal amount of 11% convertible unsecured convertible debentures, originally due October 31, 2028 (the "Convertible Debentures"). The Convertible Debentures will be redeemed by the Trustee on August 4, 2025 (the "Redemption Date"), in accordance with the terms of the Indenture. The Convertible Debentures, which are listed and posted for trading on the TSX Venture Exchange ("TSXV") under the symbol LSL.DB, will cease trading on the Redemption Date, in accordance with TSXV policies.
Read more at newswire.caLSL PHARMA GROUP ANNOUNCES REDEMPTION OF 11% UNSECURED CONVERTIBLE DEBENTURES
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.